0001209191-21-011065.txt : 20210216 0001209191-21-011065.hdr.sgml : 20210216 20210216202612 ACCESSION NUMBER: 0001209191-21-011065 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210214 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRIFFIN MICHELLE RENEE CENTRAL INDEX KEY: 0001229765 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21642133 MAIL ADDRESS: STREET 1: 19723 NE 65TH LANE CITY: KIRKLAND STATE: WA ZIP: 98033 FORMER NAME: FORMER CONFORMED NAME: BURRIS MICHELLE DATE OF NAME CHANGE: 20030429 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-14 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001229765 GRIFFIN MICHELLE RENEE C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 1 0 0 0 Common Stock 2021-02-14 4 A 0 1504 0.00 A 1504 D Common Stock 2021-02-16 4 M 0 6000 7.80 A 7504 D Common Stock 2021-02-16 4 S 0 6000 65.08 D 1504 D Stock Option (Right to Buy) 66.50 2021-02-14 4 A 0 3759 0.00 A 2031-02-14 Common Stock 3759 3759 D Stock Option (Right to Buy) 7.80 2021-02-16 4 M 0 6000 0.00 D 2029-04-23 Common Stock 6000 89000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.49 to 65.45, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Michelle Griffin by Eric Billings, attorney-in-fact 2021-02-17